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Diabetes is a chronic disease that effects 10 percent of the world’s population and causes more
than 1.5 million deaths a year and billions of dollars in associated health care cost. It can lead to
very serious complications such as renal failure, liver cirrhosis, heart attack, and vision loss. The
most common type of diabetes is type 2 diabetes. Type 2 diabetes arises when blood glucose
levels remain chronically high due to insulin resistance. The reason for this elevation is due to
the failure of insulin to allow tissues to uptake glucose causing problems in subsequent metabolic
pathways. Over the years, it has been shown that insulin regulates key enzymes in both
carbohydrate and fat metabolism. The insulin regulation of these enzymes occurs primarily via
the phosphoinositol-3- kinase / protein kinase B (PI3K/Akt) pathway. Once glucose is
transported into the cells, it is converted into glucose-6-phosphate and can enter metabolic
pathways such as the pentose phosphate pathway, and fatty acid synthesis which are regulated by
the key enzymes glucose-6-phosphate dehydrogenase (G6PDH), and fatty acid synthase (FAS),
respectively. Previously, we established an insulin resistance model using glucosamine in
primary rat hepatocytes and reported that under glucosamine induced insulin resistance, the
insulin induction of G6PDH expression was suppressed, while there was no effect on the insulin
induction of FAS expression. The mechanism of this differential regulation, however, is
unknown. We also previously reported that the insulin induction of sterol regulatory element
binding protein 1c (SREBP1c), a key transcription factor in the insulin induction of both G6PDH
and FAS was suppressed under insulin resistant conditions suggesting that it was not involved in

the differential mechanism by insulin under insulin resistant conditions. In this study, we
investigated the role of LXR, another important transcription factor in the regulation of
metabolic genes by using its agonist TO901317. TO901317 had no impact on the insulin
induction of G6PDH under normal or insulin resistant conditions. The effect of the LXR agonist
on SREBP1c was muted in the presence of glucosamine however the LXR agonist’s effect on
FAS expression was unaltered when glucosamine was present. LXR agonist did not have an
effect on the insulin induced suppression of an inhibitor of SREPB1c processing, INSIG2
expression under normal or insulin resistant conditions. Taken together, these data strongly
suggest that LXR acts as a differentiator in the regulation of FAS and G6PDH under
glucosamine induced insulin resistant conditions.
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Chapter 1
Introduction
1.1 Diabetes, Complications, and Impact

Diabetes is a disease that occurs when there is a chronically high amount of glucose in
the blood, due to either a lack of insulin which leads to type 1 diabetes, or insulin resistance
which leads to type 2 diabetes or a combination of both (1). Insulin is a hormone secreted by the
beta cells of the pancreas that allow the cells to use excess glucose in the blood to maintain
glucose homeostasis. Ninety percent of diagnosed diabetes cases are type 2 resulting from insulin
resistance (2), highlighting the importance of investigating the mechanism by which insulin
resistance evolves.
According to the Centers for Disease Control (CDC), in 2018 in the US, 34.2 million
people have been diagnosed with diabetes and 88 million have pre-diabetes which equates to 11
and 34 percent of the US population, respectively. As of 2014, an estimated 422 million people
or 8.5 percent of the world population were diagnosed with diabetes (3, 4). In the US, the
number of people diagnosed with diabetes doubled in the last 20 years while a 4-fold increase
was observed worldwide from 1980 to 2014 (3, 4). The number of deaths in the US in 2017
caused by diabetes was 270,702 and 1.5 million worldwide making it the 7th leading cause of
death (3, 4). Diabetes if not controlled can lead to life threatening damage in the heart, blood
vessels, eyes, kidneys, and nerves (3, 4). Medical care for the disease including doctor and
hospital visits and medication have risen dramatically over the years (3). The cost of diabetes in
the US including for the over 16 million people who visited the emergency room reached 327
billion dollars in 2017 according to the CDC and 825 billion dollars per year in the world
1

according to the World Health Organization (3, 4). Risk factors for diabetes include obesity, not
being physically active, smoking, and having a family member with diabetes (3).
Diabetes can be managed by changing diet, becoming more physical, taking insulin or
other medicines. Treatment for individuals with type 1 diabetes involves insulin injections or the
use of an insulin pump, frequent blood sugar checks, and carbohydrate counting. Treatment for
individuals with type 2 diabetes primarily involves lifestyle changes, monitoring blood sugar
levels, and taking diabetes medications that help with insulin sensitivity such as Metformin or
insulin or both (5). However, even with those measures people can still have high amounts of
blood glucose. Overdoing diabetic treatments can also lead to complications such as abnormally
low amounts of blood glucose which can be deadly if not treated right away.
1.2 Glucose Homeostasis
Glucose homeostasis is a process that the body utilizes for the maintenance of blood
glucose levels within a tight range of 4mM to 6mM to ensure normal body functions. This
process is maintained by the balance of insulin and glucagon that are secreted by the pancreas
(5). During fasting conditions, when blood glucose levels are low, the alpha cells of the pancreas
secrete glucagon to drive the processes that elevate the blood glucose levels through
gluconeogenesis (5). On the other hand, during feeding conditions, when the blood glucose
levels are high, the beta cells of the pancreas release insulin to stimulate the processes that lower
blood glucose levels through glycolysis, lipogenesis, glycogen synthesis, and protein synthesis
(5–8).
Insulin acts on many tissues to main glucose homeostasis such as liver, muscle, and
adipose tissues. Glucose uptake occurs when tissues such as muscle and adipose tissues take
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glucose from the circulation for their energy needs for their cell processes. Glucose uptake
occurs via moving glucose through glucose transporter 4 (GLUT4) in muscle and adipose cells.
This process is regulated by insulin via the phosphoinositol-3-kinase PI3K/ protein kinase B Akt
pathway (9). Muscle contraction also appear to enhance glucose uptake via GLUT4 on muscle
cells due to enhanced calcium release from the cells. Acylation stimulating protein (ASP) 160
plays a key role in the insulin mediation of GLUT4 activity downstream of AKT. Insulin
resistance inhibits the expression of GLUT4 leading to less glucose uptake which leads to higher
blood glucose (10–13).
1.3 Insulin and the PI3K Pathway

Insulin which plays an important role in maintaining glucose homeostasis is an endocrine
peptide hormone that is secreted by the beta cells of the pancreas in response to high glucose. It
was discovered by Banting and Best in 1922. The structure of insulin consists of two polypeptide
chains crosslinked by 3 disulfide bonds while the structure of the insulin receptor (IR) consists of
4 subunits that are joined by disulfide bonds (14, 15). The regulatory action of insulin in
response to high glucose is exerted on the target cells such as the liver and skeletal muscle by
binding to the insulin receptor located on the plasma membrane of those cells (16). When insulin
binds to the alpha subunit of the IR it activates the tyrosine kinase in the beta subunit via auto
phosphorylation of itself (Figure 1). This causes a series of activations and inactivations of
proteins inside the cells through a pathway known as the insulin signaling cascade. The tyrosine
phosphorylation of insulin receptor substrate 1 (IRS-1) by the IR activates the insulin signaling
cascade to regulate enzymes that control growth and metabolism (17).

3

The portion of the insulin signaling cascade that plays a large role in the regulation of metabolic
enzymes is called the (PI3K)/ (Akt) pathway. Upon binding of insulin to its receptor, the tyrosine
phosphorylation of IRS-1 would activate the PI3K protein by binding the p85 and p110 subunits
of the PI3K protein which induces the phosphorylation of phosphatidylinositol 4, 5-bisphosphate
(PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3) (18). PIP3 binds Akt which allows it
to translocate from the cytoplasm and bind the cell membrane. Then phosphoinositide-dependent
protein kinase-1 (PDK-1) binds Akt and allows for the phosphorylation of Akt at Thr308 (19).
The phosphorylation of Akt at Thr308 allows for the activation of the mammalian target of
rapamycin (mTOR pathway) and DNA-PK. MTORC2, which is part of the mTOR pathway, and
DNA-PK phosphorylate Akt at Ser473. Those two phosphorylation events on Akt in response to
insulin lead to the full activation of Akt. The full activation of Akt stimulates and inhibits key
effectors that play a role in the regulation of metabolic pathways and processes such as glucose
homeostasis. For example, Akt phosphorylates glycogen synthase kinase (GSK3β) at Ser9 and
Ser21 in response to insulin which activates glycogen synthase (GS), an important enzyme in the
conversion of excess glucose to glycogen (19). Akt also activates the (mTOR) pathway by
activating the mTOR complex 1 (mTORC1) protein and Ras homolog enriched in brain (RHEB)
protein by inhibiting both tuberous sclerosis complex 1 (TSC1) and tuberous sclerosis complex 2
(TCS2). The RHEB protein which is a Ras dependent protein also assists in the activation of
mTORC1 complex (20). The activation of the mTOR pathway leads to the activation of sterol
regulatory element binding protein 1c (SREBP1c), an important transcription factor in the
regulation of lipogenesis (21, 22). Akt has been shown to also phosphorylate forkhead box
protein O 1 (FOXO1), an important transcription factor in the activation of gluconeogenesis,
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which leads to its translocation from the nucleus to the cytoplasm to be degraded by the 14-3-3
protein degradation process (23).

1.4 Metabolic Pathways Regulated by Insulin
1.4.1 Fatty Acid Synthesis

Fatty acid synthesis is an important metabolic pathway for energy and glucose
homeostasis (24). It is a pathway that allows for the conversion of excess glucose from high
carbohydrate diets into fatty acids. Fatty acids are precursors need to synthesize molecules for
the purpose of energy storage for future need. Similar to many other metabolic pathways, fatty
acid synthesis is tightly regulated by hormonal and nutritional status such as high insulin / low
glucagon in response to feeding and fasting (25). Fatty acid synthesis occurs in the cytosol and
the endoplasmic reticulum (ER) of cells of the liver and adipose tissues. During the process of
fatty acid synthesis, a sequential extension of an alkanoic chain two carbons at a time occurs
where acetyl units derived from either glucose or acetate are added to an initial starting molecule
such as acetyl coenzyme A (CoA). This is followed by a series of reductive biosynthesis
reactions to form the 16-carbon palmitate. The following equation summarizes the production of
palmitate from acetyl CoA.

8 Acetyl CoA+ 7ATP+ 14NADPH+ 14H+

→

14NADP++6H2O
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Palmitate+ 7ADP+ 7Pi + 8CoA+

The first committed step in the synthesis of fatty acids is catalyzed by the enzyme acetyl
CoA carboxylase (ACC) which converts acetyl CoA to malonyl CoA. The process of fatty acid
synthesis from malonyl CoA, the second committed step in fatty acid synthesis, is catalyzed by a
single multifunctional enzyme called fatty acid synthase (FAS) (26). This process starts with
condensation of the acetyl and malonyl moieties coupled with an energetically favored
decarboxylation to form an acetoacyl, a beta-ketoacyl. The acetoacyl is then reduced to form the
fatty acyl-CoA that condenses again with another malonyl moiety to form an elongated betaketoacyl (24, 25). Seven cycles of chain extension and beta carbon processing according to the
equation above form the 16-carbon palmitate. Palmitate is then converted to triglycerides for
storage (27).

1.4.2 Pentose Phosphate Pathway

The Pentose Phosphate Pathway (PPP) is another pathway that is important to glucose
homeostasis. Its role in glucose homeostasis is to shunt glucose away from glycolysis to provide
needed molecules for other cellular functions. The goal of this pathway is to provide precursors
necessary for nucleotide and amino acid biosynthesis and fatty acid synthesis. It also provides
the reducing agents needed for anabolism and to combat oxidative stress. Discovered in the
1930s by Warburg, the pathway converts glucose-6-phosphate (G6P) into carbon dioxide (CO2),
and produces nicotinamide adenine dinucleotide phosphate (NADPH) and ribulose 5- phosphate
in the oxidative branch. The non-oxidative branch then starts with ribulose 5 phosphate being
isomerized to form ribose-5-phoshate and xylulose-5-phoshate, molecules needed for nucleic
acid synthesis. If there is no need for nucleic acid synthesis, then the pathway would supply the
6

metabolites that are in need for glycolysis (28). The committed step of PPP is the enzyme
glucose-6-phosphate dehydrogenase (G6PDH). Similar to fatty acid synthesis, PPP is tightly
regulated by hormonal and nutritional status, including high insulin due to feeding, and high
glucagon due to fasting (29).

1.5 Importance of the Regulation of Gene Expression and Posttranslational Modification in the
Control of Metabolic Pathways

Flux through the metabolic pathways is controlled by their regulatory enzymes. Enzyme
activity can be regulated by the controlling the expression of its corresponding gene. Gene
expression according to the National Human Genome Research Institute is a process by which
the cell uses the information encoded in the DNA to direct the synthesis of a functional protein
of the cell. During this process, the cell transcribes a messenger RNA from the DNA in a process
called transcription. This messenger RNA then undergoes a process called translation where the
translation RNA reads the sequence of the messenger RNA by groups of 3 bases which
correspond to 1 of each 20 amino acids to build a protein sequence in the ribosome.
Subsequently to the synthesis of the protein, phosphorylation and glycosylation can change the
function via changing the conformation of a protein. These posttranslational modifications play
an important role in activating and deactivating signaling pathways that are important for cellular
functions. Insulin regulates the rate of protein synthesis for the regulatory enzymes in the
metabolic pathways by altering the expression of the gene that codes for the subsequent protein
or altering the translation of the mRNA into protein sequences. Insulin also regulates the
posttranslational modifications of many proteins in it signaling pathway such as its inhibitory
effect on FOXO1 via phosphorylation. Insulin regulates the expression of over 100 genes via its
7

signaling pathway, with most of metabolic processes it regulates occurring via the PI3K pathway
(30). In gluconeogenesis for example, FOXO1, a transcription factor, binds the iron response
element (IRE) unit of the promoter regions of phosphoenolpyruvate carboxykinase (PEPCK) and
glucose 6-phosphatase (G6pase) to activate the expression of those genes for enzyme synthesis
(31). That binding is inhibited when insulin phosphorylates FOXO1 which translocates it from
the nucleus to the cytoplasm to initiate degradation.
1.6 Genes Involved in the Regulation of Fat Synthesis
1.6.1 Fatty Acid Synthase (FAS)

FAS is a complex homodimeric (552 kDa) enzyme that regulates de novo lipogenesis by
catalyzing the synthesis of the free fatty acid (FFA) palmitate, a 16-carbon chain fatty acid, from
acetyl CoA and malonyl CoA in a NAPDH dependent manner (32, 33). FAS is also responsible
for the synthesis of other fatty acids such as myristate, laureate, and shorter chain fatty acids
(34).
Like many enzymes that regulate metabolic pathways, changes in the nutritional status
alters the amount of FAS present. For example, FAS is upregulated in response to diets with high
carbohydrate (35). Polyunsaturated fats reduce the expression of FAS by inhibiting SREBP1c, a
key transcription factor in the regulation of FAS expression (36, 37). Under normal fasting
conditions, glucagon via cAMP inhibits the expression of FAS in rat liver, while under feeding
conditions, insulin stimulates the expression of FAS. Under diabetic conditions however, refeeding
did not stimulate the increase in FAS expression compared to normal conditions, an indication in
type 1 diabetes that the insulin induction of FAS is severely reduced (38). In obese mice, insulin
resistance reduces glucagon inhibition of fatty acid synthesis, an indication that insulin resistance
8

leads to higher fatty acid synthesis (39). As shown in Figure 1, FAS is induced by insulin via the
PI3K/Akt pathway that activates a series of transcription factors that are involved in the expression
of FAS (40). One transcription factor, SREBP1c, which binds to the SRE element of the promoter
region of FAS is regulated by signal proteins such as mTOR which is downstream of Akt (41).
Another transcription factor that is involved in the regulation of FAS expression in response to
insulin is LXR, which binds to the LXRE element of the promoter region of FAS (42). USF,
downstream of PP1, is an effector of Akt that binds to the EBOX of the promoter of FAS and
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regulates the expression of FAS by recruiting SREBP1c to the promoter. USF has been shown to
be an absolute requirement for insulin induction of FAS expression (43–45).

Figure 1. Schematic Diagram Showing the Insulin Induction of FAS Expression Via the
PI3K/Akt Pathway.
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1.7 Genes Involved in the Regulation of the PPP
1.7.1 Glucose 6 Phosphate Dehydrogenase (G6PDH)

G6PDH is a housekeeping enzyme that catalyzes the rate determining step of the
oxidative phase of the PPP (46). It was first discovered in 1931 in red blood cells and yeast and
is found in most cell types in the body (47). It controls the flux of oxidative PPP which
determines how much of the G6P gets shunted into the PPP. G6PDH is present in both
monomeric and dimeric forms which are inactive and active, respectively (48). G6PDH which is
a highly specific enzyme for NADP+, a precursor for NADPH, makes it an important source of
NADPH which is needed for fatty acid synthesis and maintaining redox balance (49). G6PDH is
typically present in tetramer form that cannot be inhibited by NADPH. However high pH and
ionic strength can cause the dissociation of the tetramer to a dimer which allows NADPH to
inhibit G6PDH activity by dissociating the dimer form of G6PDH to the inactive monomer form
of G6PDH (50). Similar to many regulatory enzymes in other metabolic pathways, G6PDH is
regulated by hormonal and nutritional status such as high insulin /low glucagon in response to
feeding and fasting (50, 51). Carbohydrate increases the expression and activity of G6PDH while
polyunsaturated fatty acids inhibit the expression of G6PDH in rats and mice (52, 53). AMPK is
a key mediator in the inhibition of G6PDH by polyunsaturated fatty acids in rat hepatocytes (54).
Similar to FAS, insulin induces the expression of G6PDH via the mTOR pathway downstream of
Akt (figure 2) which leads to the activation of SREBP1c that binds to the SRE element of the
promoter of G6PDH (55). SREBP1c acting as a key regulator of gene expression of G6PDH
was shown by the overexpression of SREBP1 in HEK-293 cells, suggesting a role for SREBP1c
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in the insulin regulation of G6PDH (56). Unlike FAS, the G6PDH promoter region does not
contain a site for the liver x receptor suggesting that the liver x receptor does not regulate
G6PDH (57).

Figure 2. Schematic Diagram Showing the Insulin Induction of G6PDH Expression Via the
PI3K/Akt Pathway.

12

1.8 Transcription Factors Involved in the Regulation of FAS and/or G6PDH
1.8.1 Sterol Regulatory Element Binding Protein 1c (SREBP1c)

SREBPs are a family of proteins around 1150 amino acids long and are primarily bound
to the endoplasmic reticulum (ER). They are regulated in various ways which include
transcription, proteolytic cleavage of the precursor for release off the ER, and posttranslational
modifications (50). The three forms of SREBP are SREBP1a, SREBP1c, and SREBP2.
SREBP1c is involved in fatty acid synthesis and storage, SREBP1a is involved in global lipid
synthesis and cell growth, and SREBP2 is involved in cholesterol biosynthesis. SREBP1a is only
predominant is certain tissues such as intestinal, epithelial, heart, macrophage, and bone marrow
dendritic cells. SREBP1c however, is the predominant isoform in most other tissues (56). In the
liver, where fat synthesis occurs, SREBP1c is expressed 10 times more than SREBP1a making it
the major isoform in the liver (60). SREBPs are synthesized as a precursor (pSREBP) bound to
the SREBP cleavage-activating protein (SCAP)/INSIG complex. This complex is bound to the
ER to keep SREBPs in the inactive form. In response to signaling molecules such as insulin,
INSIG expression is inhibited. This inhibition then allows the dissociation of SREBPs from the
ER. SREBPs are then translocated to the golgi apparatus via binding to the Sec23/24 proteins of
the coat protein complex II (COPII) vesicles. Once in the golgi, they are cleaved by site 1
protease (S1P) and site 2 protease (S2P) to become the mature active form of SREBPs
(nSREBP) (61, 62).
Insulin regulates exclusively SREBP1c transcription and proteolytic processing in the
liver via the mTOR pathway (63, 64). The role of the mTOR pathway in the insulin induction of
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SREBP1c expression was confirmed when rapamycin, an inhibitor of the pathway was added in
mouse liver cells and in diabetic mice (65).
For insulin to fully activate the transcription of SREBP1c, the binding of several
transcription factors is required including SREBP1c itself, liver x receptor (LXR), nuclear factor
Y (NF-Y), and specificity protein 1 (SP-1) (66). SP-1 and NF-Y play a role in activating the SRE
region of the promoter to help insulin induce the transcription of SREBP1c (66). LXR plays a
role in the insulin induction of SREBP1c via binding two LXRE sites in the promoter of
SREBP1c which along with the serum response element (SRE) site plays a cooperative role in
insulin induction of SREBP1c via LXR (67). FOXO1, a transcription factor involved in the
activation of gluconeogenesis has been shown to be an inhibitor of SREBP1c via two
mechanisms. The first mechanism is inhibiting the transcriptional activity of LXR by inhibiting
LXR binding to the LXRE in mouse liver and HEPG2 cells (68, 69). The second mechanism is
inhibiting SP1 and SREBP1c transcriptional activity on the SRE unit of the promoter of
SREBP1c in mouse livers and primary rat hepatocytes (70, 71).
In addition to the insulin induction of SREBP1c expression, insulin also induces the
proteolytic processing of SREBP1c, a requirement for its activity on its target genes. Insulin, via
P70 S6 kinase, which is downstream of the mTOR protein, phosphorylates the pSREBP1c which
increases the affinity of the SREBP1c-SCAP complex to the Sec23, 24 of the COPII (72, 73).
Insulin also induces SREBP1c processing by suppressing INSIG2 in an mTOR independent
manner which allows for the dissociation of pSREBP1c from the ER, a requirement for the
initiation of processing of pSREBP1c (74, 75).
On the other hand, glycogen synthase kinase 3β (GSK3β) an inhibitor of glycogen
synthesis, has been shown to inhibit SREBP1c processing by phosphorylating it at Ser73 which
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initiates its degradation (76, 77). AMPK also inhibits SREBP1c processing by phosphorylating it
at Ser372 (78).
1.8.2 Liver X Receptor (LXR)
Liver X Receptors are nuclear receptors that are very important for regulating lipid metabolism.
They exist in two isoforms, LXRα and LXRβ. LXRα was cloned in 1995 by Patricia Willy and
shown to form a heterodimer with the RXR to bind to the LXRE site in the promoter regions of
the target genes (79). LXRβ which is also known as OR-1 was cloned by Teboul in 1995 (80).
LXRα is highly expressed in liver, kidney, intestine and adipose tissues, whereas LXRβ is
expressed in nearly all tissues (81). LXRβ is mainly involved in cholesterol synthesis (82) while
LXRα has been shown to be an important transcription factor in the regulation of lipogenic genes
via binding to the LXRE element in the promoter region of its target genes such as FAS and
SREBP1c (83, 84). The binding of LXR to the LXRE elements of SREBP1c and FAS was
confirmed in studies done by Liang and Joseph using expression plasmids of LXR and
nSREBPs, and by using LXR agonist TO901317 in culture and whole animal hepatocytes (83,
84). These studies also confirmed LXR as a key transcription factor in the induction of SREBP1c
and FAS using knockout and overexpression studies in cultured hepatocytes and in fed mice (83,
85). LXR can also induce the expression of FAS independent of SREBP1c. This independency
was confirmed by overexpression and inhibition of SREBP1c studies in mice liver (42, 83). LXR
has been shown to be a key transcription factor in the insulin induction of FAS expression via
SREBP1c. This induction requires the LXR binding to C/EBPβ, another key transcription
involved in the transcription of SREBP1c in rat hepatocytes and livers from whole mice (86, 87)
LXR can be activated independent of insulin via O-glycosylation in response to high glucose and
glucosamine leading to higher induction of its target genes in culture and diabetic mice (85, 88,
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89). AMPK, which is inhibited by insulin has been shown to inhibit LXRα activity by
phosphorylating it at an unknown threonine residue and via the inhibition of S6K1 in the livers
of whole mouse fed with high fat diet and HEPG2 and rat hepatoma cell lines (90, 91).

1.8.3 Insulin Induced Gene (INSIG)
INSIGs are recently discovered genes that are involved in the regulation of lipogenesis
and cholesterol synthesis. The INSIG family consists of 2 isoforms, INSIG1, also known as CL6, and INSIG2. INSIGs regulate lipid metabolism and cholesterol synthesis via binding to SCAP
proteins and 3-hydroxy-3-methyl-glutaryl (HMG) reductase, an enzyme involved in cholesterol
synthesis (92). INSIG1 was first discovered in liver and fibroblast cells in the 1990s (93).
INSIG2 was discovered in 2002 in hamster ovary cells. INSIG1 and INSIG2 are 59 percent
identical. INSIGs play an important role in the inhibition of SREBP processing. In the presence
of sterols, INSIG2 blocks the processing of SREBP (74). With INSIGs being an inhibitor of
SREBPs including SREBP1c, INSIGs play a large role in the antilipogenic effect on the liver.
INSIGs being a modulator of lipogenesis have been confirmed by overexpression studies of
INSIGs performed in livers of obese mice (94). Insulin regulates SREBP1c induced lipogenesis
by reducing the expression of INSIG2 causing the dissociation of the SCAP-SREBP1c complex
from INSIG2 protein allowing the complex to be released from the ER to begin SREBP1c
processing (95). During long term insulin treatment, insulin would induce expression of INSIG1
due to increased nSREBP1c since INSIG1 is a target of nSREBP1c. This might limit SREBP1c
processing since INSIG1 is also an inhibitor of SREBP1c (75). This was confirmed by a study
that showed that overexpression of INSIG1 limited the processing of insulin induced SREBP1c
processing via inhibiting INSIG2 (96). It has also been shown that the insulin induced processing
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of SREBP1c via suppressing INSIG2 occurs downstream of Akt but independent of the mTOR
pathway (20).
1.9 Types of Insulin Resistance
Insulin resistance occurs when the target cells, such muscle, liver, or fat cells, do not
respond well to insulin. Genetic defects of the genes that code for certain proteins in the insulin
signaling cascade starting with insulin receptor and IRS-1 can cause insulin resistance (97–99).
Also, lipid and fatty acid accumulation, oxidative stress, O-glycosylation, and ER stress can
cause insulin resistance (15). When insulin resistance leads to chronically higher than normal
levels of blood glucose, the person will be classified as a patient with type 2 diabetes. For more
than a half century, insulin resistance and type two diabetes have been linked to each other,
therefore insulin resistance is so far the most powerful predictor of type 2 diabetes (96).

1.9.1 Hexosamine Biosynthetic Pathway and Insulin Resistance
The hexosamine biosynthetic pathway (HBP) is a metabolic pathway that branches off
glycolysis at fructose-6-phoshphate (F6P) to produce UDP-N-acetylglucosamine from glucose
(UDP-GlcNAc), acetyl CoA, glutamine, and UTP. UDP-GlcNAc is a precursor needed for the
activation of O-glycosyl transferase (OGT) which is responsible for the O-glycosylation of
proteins and lipids (101). HBP was first linked to insulin resistance by Marshall in 1991. The
role of glutamine fructose-6-phosphate amidotransferase (GFAT) and OGT in decreasing the
insulin response and decreasing glucose tolerance were confirmed by overexpression of OGT in
transgenic mice and inhibiting GFAT (102, 103). Glucosamine, a carbohydrate that bypasses
GFAT and drives the HBP forward without any control, was able to decrease insulin sensitivity
and glucose tolerance by decreasing IRS-1 phosphorylation which inhibited its association to the
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p85 subunit of the PI3K protein (104–106). Downstream of PI3K, the insulin induction of mTOR
was also shown to be weakened in response to glucosamine (107). This indicates that
glucosamine induces insulin resistance by affecting IRS-1 activity which leads to the weakening
of downstream signaling pathways such as the PI3/Akt pathway.
1.9.2 Oxidative Stress Induced Insulin Resistance
Oxidative stress occurs when excess endogenous reactive oxygen species (ROS) damage
the cells and manipulate signaling pathways (108). Examples of ROS include superoxide and
hydrogen peroxide. ROS are mostly generated in the electron transport chain of the mitochondria
when the proton motive force is high and the coenzyme Q pool is reduced leading to less ATP
made (109). ROS are also generated via activating enzymes such NAPDH oxidase (NOX) and
endothelial nitric oxide synthase (eNOS) outside the mitochondria (110). While a minimal
amount of ROS is needed to maintain important cellular functions, an excess of ROS can lead to
cellular damage resulting from modification of the thiol groups on cystine residues of proteins
when can alter their function (111). Hyperglycemia induces oxidative stress via to the activation
of PKC in endothelial cells which drives glucose flux through the polyol pathway. The polyol
pathway is a pathway that allows the conversion of glucose to sorbitol via aldose reductase and
then to fructose via aldose reductase dehydrogenase. In this process, NAPDH gets oxidized to
NADP+ (112). The less NADPH means less reduced glutathione available to combat oxidative
stress. This results in the generation of ROS such as superoxide (113–115).The production of
superoxide leads to the inhibition of glyceraldehyde-3-phosphate which leads to more glucose
being shuttled through the HBP pathway (116). These studies indicate that hyperglycemia leads
to oxidative stress by enhancing the production of ROS which can lead to the increased shuttling
of glucose via HBP.
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Hyperglycemia induced oxidative stress decreases the mitogen activated protein kinase
phosphatase 1(MKP-1) in rat vascular smooth muscle cells that leads to excessive p38 mitogen
activated protein kinase (MAPK) pathway activation (117). The c-Jun N-terminal kinase (JNK)
pathway, is a pathway that is stimulated by stress and inflammation via the activation of mitogen
activated protein kinase kinase 4 (MKK4) and mitogen activated protein kinase kinase 7
(MKK7) of the MAPK family as a result of stress and inflammation. The activation of the JNK
pathway involves the phosphorylation of JNK by MKK4 and MKK7 in response to stress
indicators at Tyr184 and Thr183 respectively. These phosphorylation events allow the
translocation of JNK to the nucleus which phosphorylates the c-Jun protein at Ser63 and Ser73
leading to the activation of many proteins involved in cell proliferation and apoptosis (118–122).
The JNK pathway has been shown to phosphorylate IRS-1 at Ser307 leading to the inhibition of
IRS-1 activity which can lead to insulin resistance (123). Oxidative has been shown to induce
insulin resistance via decreasing IRS-1 and IRS-2 protein levels leading to a decreased Akt
activity (124). It has also been shown that oxidative stress mediated by FOXO1 translocation to
the nucleus is due to active JNK pathway also induces beta cell dysfunction triggering type 1
diabetes. FOXO1 induced beta cell function by the induction of the JNK pathway was confirmed
by the inhibition of the insulin promoter factor- 1 (PDX-1), an important protein in the
maturation of β-cells to secrete insulin (125, 126). This is an indication that oxidative stress is
important inducer of insulin resistance through reducing the insulin signaling via IRS-1, and
reducing insulin secretion from the beta cells, triggering both type 1 and type 2 diabetes.
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1.9.3 Palmitate Induced Insulin Resistance
Palmitate has been linked to insulin resistance through oxidative stress inhibiting the
PI3K pathway. Protein tyrosine phosphatase 1B (PTP-1B), a negative regulator of the tyrosine
phosphorylation of IR and IRS-1, protein levels were elevated in c2c12 skeletal cells under
palmitate induced insulin resistance leading to the reduction of tyrosine phosphorylation of IRS1 leading to a reduction in the PI3K/Akt pathway activity. The role of PTP-B1 as a key factor in
palmitate induced insulin resistance was confirmed by knocking out PTP-B1 in skeletal cells
(127). Another way that palmitate induces insulin resistance is via oxidative stress. An increase
in ROS species produced leading increase in the phosphorylation of p38 MAPK and JNK. The
increase in the activity of the p38 MAPK and JNK proteins leads to a reduced tyrosine
phosphorylation of IRS-1 which leads to a reduced insulin inhibition of gluconeogenic genes via
the PI3K pathway thereby increasing gluconeogenesis. The increase in gluconeogenesis leads to
elevated glucose levels, a consequence of insulin resistance, causing diabetes (128–130). The
role of JNK in palmitate induced insulin resistance effect on the PI3K/Akt was confirmed by
inhibiting the JNK pathway in H4IIE cells leading to the restoring of PI3K/Akt pathway activity
(130).

1.10 Insulin Resistance and Fatty Acid Synthesis and PPP
Interestingly, while palmitate induced insulin resistance reduces the insulin inhibitory
effect on gluconeogenesis, the insulin induction of fatty acid synthesis is not affected as evident
by the increase in the expression of lipogenic genes and the steady amount of FFA shown in
culture and whole animals (131, 132). The buildup of fatty acids in response to insulin resistance
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leads to excess lipid storage in the liver which develops the condition called Non-Alcoholic Fatty
Liver Disease (NAFLD) (133). NAFLD can range from excess fatty liver, to hepatic steatosis to
liver cirrhosis due to excess fat from lipolysis in the adipose tissues, to excess lipogenesis, and
decreased fatty acid oxidation in the liver (134, 135). There is a strong link between obesity
induced insulin resistance and NAFLD as more than 90 percent of patients with type 2 diabetes
have NAFLD (136). NAFLD can further enhance insulin resistance via elevated levels of
SREBPs. In obese mice and rat hepatocytes, elevated SREBP1c activity leads to a reduction in
IRS-2 protein levels. The reduction of IRS-2 activity leads to lower Ser473 Akt phosphorylation
which leads to higher gluconeogenic gene expression resulting in lower glucose tolerance. The
role of SREBPs as an important mediator in inducing insulin resistance via decreasing IRS-2
mediated insulin signaling was confirmed using overexpression and knockout of SREBP1c in
mice livers (137–139).
There has been conflicting evidence on the role or regulation of G6PDH in insulin
resistance and hence PPP. For example, it has been shown that high glucose activates the PKA
pathway in endothelial cells which inhibits the expression and activity of G6PDH which
contributes to increased oxidative stress These findings were also shown in STZ treated rat
endothelial cells (140, 141). It has also been documented that G6PDH activity and expression is
reduced under type 1 diabetes as shown in STZ treated mice livers (142). This indicates that high
glucose in STZ treated mice via the PKA pathway might result in decreased G6PDH expression
and activity. Others have shown that G6PDH contributes to insulin resistance by increasing
oxidative stress and increasing lipogenesis via increasing NADPH available for fatty acid
synthesis (143) On the other hand, G6PDH over expression leads to larger β-pancreatic cells
which leads to improved insulin secretion under hyperglycemic conditions (144).
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1.11 LXR and Insulin Resistance

LXR has been shown to have antidiabetic effects in studies using the LXR agonist. LXR
agonist is a synthetic ligand that binds to LXR to cause its activation. There are many agonists
for LXRs, once of them is TO9013137 which has been shown to induce a 3.5-fold activation
increase in LXRα compared to a 1.5-fold activation of LXRβ (145). Overactivation of LXR via
its agonist has been shown to improve glucose tolerance, due to inhibition of oxidative stress
which leads to the deactivating of the JNK pathway. The deactivation of the JNK pathway leads
to increased insulin sensitivity by restoring Akt activity. The restoration in Akt activity leads to
the reduction of gluconeogenic gene expression which leads to decreased glucose output in
culture and diabetic obese mice (132, 146, 147). The decrease in glucose outpoint is correlated
with increased glucose uptake due to an elevation in glucose transporter 4 (GLUT4) expression
and activity in adipocytes of (147, 148). Interestingly, mice treated with LXR agonist for 3
weeks via intraperitoneal injection resulted in the induction of insulin resistance due to increased
lipogenesis as evident by an increase in free fatty acids, hyperinsulinemia, and decreased glucose
tolerance (149). These results indicate that despite LXR having antidiabetic effects, prolonged
treatment with LXR might induce insulin resistance due to the induction of fatty acid synthesis,
suggesting more studies are needed to clarify.
1.12 Significance and Hypothesis
Treatment of insulin resistance, a hallmark of type 2 diabetes, has been a goal of scientists
and health care professionals for years. Therefore, it is important to fully understand the
mechanism of insulin resistance to help find the treatment. Understanding the mechanism helps
identify potential proteins to target with synthetic drugs. It is also important to find out whether
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that target protein regulates other pathways not involved in insulin signaling due to the side
effects that may arise from inhibiting or overactivating that target protein. It is also important to
understand the different mechanisms of insulin resistance and their effects on the metabolic
pathways since insulin resistance might have different effects on the different metabolic
pathway. For example, as discussed before fat induced insulin resistance suppresses the insulin
inhibitory effect on gluconeogenesis but leaves the insulin induction of fatty acid synthesis
unabated. How this happens is still not well understand. Understanding the effect of insulin
resistance on metabolic pathways may lead to inventing drugs that directly address the
dysregulation of the metabolic pathways. These drugs will lead to a significant improvement in
treatment of diabetes since current diabetic medicines only address insulin sensitivity and
glucose uptake and urine excretion. These medicines do not address the core of the problem
which is the dysregulation of metabolic pathways due to insulin resistance.
Many models of insulin resistance have been established in animals and cells in culture.
One of those models uses glucosamine to stimulate the HBP and has been adapted in our lab.
Evidence shows that palmitate induced insulin resistance leads to the activation of the HBP
(150). Initial evidence that we have in our lab shows that insulin regulates G6PDH and FAS, the
key enzymes in PPP and fatty acid synthesis, respectively differently under glucosamine induced
insulin resistance. However, the reason for this regulation is not well understood. Therefore, the
goal of this study is to find the differentiator that is responsible for the differential regulation of
the gene expression of FAS and G6PDH under glucosamine induced insulin resistance.
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Chapter 2
Materials and Methods
2.1 Hepatocyte Isolation and Treatment
Male Sprague Dawley Rats SAS SD strain code 400 were purchased from Charles Rivers
Laboratories Kingston NY. Rats were housed in the Institutional Animal Care and Use
Committee approved facility at Western Michigan University and maintained on Rodent Diet
5001 rat chow with drinking water ad libitum under 12-hour light and dark cycles until they
weighed over 240g. Animals were food deprived 48 hours prior to hepatocyte isolation and
anesthetized with 50mg/kg of Pentobarbital via IP injection prior to hepatocyte isolation.
Hepatocytes were isolated using the collagenase hyaluronidase perfusion and digestion method
(151). Briefly, the liver was first perfused via the portal vein with a perfusion solution containing
0.102M sodium chloride, 0.0087M sucrose, 0.0151M HEPES, 0.0005M EGTA and > 5400 units
heparin sodium salt from porcine intestinal mucosa (H3149, Sigma Aldrich) at a rate of
50ml/min for a minimum of 2 minutes prior to switching to the digestion solution. Then the
digestion solution containing 0.102 M sodium chloride, 0.0087M sucrose, 0.0151M HEPES,
0.002M potassium chloride, 0.001M calcium chloride dihydrate, 30mg/l trypsin inhibitor from
glycine max (T6522, Sigma Aldrich) and 0.05g of 300 unit/mg collagenase type 4 (LS004188,
Worthington) was run through the liver at a rate of 50ml/min for a maximum of 2 minutes. Cells
were isolated through a sterile double layered cheese cloth using a solution containing 0.102M
sodium chloride, 0.0087M sucrose, 0.0151M HEPES, 0.002M potassium chloride, 0.001M
calcium chloride dihydrate, 30mg/l trypsin inhibitor from glycine max (T6522, Sigma Aldrich)
and 0.5 percent Bovine Serum Albumin (BSA) (A9418, Sigma Aldrich).
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The hepatocytes were washed twice with Waymouth media MB-752/1 (W1625, Sigma
Aldrich) with 0.5 percent BSA (A9418, Sigma Aldrich) by centrifugation at around 560 rpm for
3 minutes. Cell count and viability was estimated using a hematocytometer and the trypan blue
dye exclusion method. The cells were then plated at 90 % confluency on sterilized Falcon
60x15mm tissue culture dishes coated with collagen type 1 from rat tail (CB-40236, Corning)
and incubated at 37 degrees Celsius for 4 hours. Cells were then washed and incubated at 37
degrees Celsius in Waymouth media MB-752/1 overnight under a humidified atmosphere of 5 %
CO2 and 95 % air at 37 °C. The cells were next washed and incubated in DMEM low glucose
media with no phenol red (11054020, Gibco) and supplemented with 0.29g/l of glutamine, 0.1g/l
of streptomycin salt, and 0.15g/l penicillin G. Treatment with bovine insulin (I-1882 Sigma
Aldrich), glucosamine (G1514, Sigma Aldrich), TO901317 (T2320, Sigma Aldrich), DMSO, or
combination of those treatments were added to the cell culture media containing the hepatocytes.
The treatments are summarized in Table 2.

Table 2. Treatment Schedule for Primary Rat Hepatocytes in Low Glucose Media in Culture.
Treatment

Enzyme

Glucosamine (G)
(1mM)

Insulin (I)
(44nM)

TO901317
(T)
1uM

DMSO

G6PDH

18 hrs.

18 hrs.

18 hrs.

18 hrs.

SREBP1c

18 hrs.

18 hrs.

18 hrs.

18 hrs.
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Table 2 —continued
FAS

18 hrs.

18 hrs.

18 hrs.

18 hrs.

INSIG2

18 hrs.

18 hrs.

18 hrs.

18 hrs.

2.2 RNA Isolation
Media was aspirated from the cells, and 200µlto 300µl of Trizol Reagent (15596018,
Thermofisher Scientific) were added to the plate. The cells were scraped and then were
transferred into a microcentrifuge tube. The samples were incubated for 5 minutes at room
temperature and then 0.2ml of chloroform isoamyl alcohol 24:1 (v: v) (C0549, Sigma Aldrich)
per 1 ml of Trizol was added to the samples. The samples were mixed by pipetting up and down
several times and incubated for 3 minutes at room temperature. Then the samples were
centrifuged for 15 minutes at 12000xg at 4 degrees Celsius. The top clear layer was transferred
to a new tube, and 0.5ml of 2-propanol was added per 1 ml of Trizol used. The samples were
mixed by pipetting up and down several times and incubated for 10 minutes at room temperature,
and then centrifuged for 10 minutes at 12000xg at 4 degrees Celsius. The supernatant was
removed, and the RNA pellet was resuspended and washed twice with ice cold 75 percent
ethanol. The RNA pellet was resuspended and dissolved in nuclease free water and the
concentration and the purity of the RNA was measured using a Thermo Scientific nano drop
spectrophotometer.

2.3 RT-PCR
4µg of cDNA were synthesized using the High-Capacity cDNA Reverse Transcription kit
with RNase inhibitor (4374966, Thermofisher Scientific). Briefly, 10µl of isolated RNA solution
containing 4µg of RNA was added to10µl of master mix containing the reverse transcription
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buffer, reverse transcriptase, RNAase inhibitor, and random primers. The mixture was then
incubated at 37 degrees Celsius for 2 hours in a thermocycler. Then qRT- PCR was performed
using the 96 well optical microplate. Each well contained 5µl of cDNA solution (100ng of
cDNA), 1µl of primer solution, 4µl of nuclease free water, and 10µl of TaqMan Fast Advanced
Master Mix solution (4444556, Thermofisher Scientific). The primers used for the various
reactions are summarized in table 2-2. The qRT-PCR was performed in a Step One Plus Real
Time PCR machine (4376600, Thermofisher Scientific) in 40 cycles where each cycle was 95
degrees Celsius for 1 second and 60 degrees Celsius for 20 seconds, after initial incubation at 50
degrees Celsius for 2 minutes and 95 degrees Celsius for 2 minutes. The results were obtained by
measuring mRNA fold change compared to no addition which was set at one. β-actin (ACTB)
was used as an endogenous control.

Table 3. Primers Used for RT-PCR.
Primer

Catalog

G6PD

Rn01529640_g1

SREBF1

Rn01495769_m1

FASN

Rn00569117_m1

ACTB

Rn00667869_m1

INSIG2

Rn00710111_m1

2.4 Protein Assay
Media was aspirated from cells after treatment. Cells were washed one time with ice cold
phosphate buffered saline (PBS). Then 100µl of radioimmunoprecipitation assay (RIPA) buffer
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(R-0278, Sigma Aldrich) containing 1:100µl of protease cocktail inhibitor (P-8340, Sigma
Aldrich) was added to each plate. Cells were scraped and the lysate was transferred to a
microcentrifuge tube and incubated for 5 minutes on ice. The lysate was then centrifuged at
8000xg for 10 minutes and the supernatant was transferred to a new cold microcentrifuge tube.
The sample protein concentration was then assessed using Pierce BCA protein assay kit (Thermo
Scientific) according to the protocol supplied by the vendor. Briefly, samples were first diluted
by 10-fold. Then 10µl of protein sample was mixed with 200µl of a 50:1 (v: v) dilution of
solution A and B and incubated at 37 degrees Celsius for 30 minutes. The absorbance of the
BCA/copper/protein complex was measured at 562nm wavelength, and the concentration was
determined by plotting against a standard curve utilizing various concentrations of BSA.

2.5 Western Blots
For the western blot analysis, 30µg of total protein was mixed with 3.33 ul of 6x Lamenli
sample buffer (J61337, Alfa Aesar) and diluted with water for a total volume of 20µl. The
mixture was heated to 70 degrees Celsius for 10 minutes and then loaded and separated on a 10
percent Tris-SDS polyacrylamide gel at 150V. The proteins in the gel were transferred onto a
PVDF membrane using the semi dry method at 20V for 8 minutes (IB401001, Thermofisher
Scientific). The membranes were incubated in blocking buffer (5 percent skim milk in TBS
containing 0.1 percent Tween 20 and then washed 3x for 5 minutes each with TBS containing
0.1 percent Tween 20. The membranes were incubated in primary antibody (table 2-3) in 5
percent fat free BSA in TBS containing 0.1 percent Tween 20 with the recommended dilutions
by the manufacturer overnight at 4 degrees Celsius. The membranes were washed 3x for 5
minutes each to remove the primary antibody with TBS containing 0.1 percent Tween 20. The
membranes were then incubated in the secondary antibody (table 2-4) in a solution of 5 percent
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fat free BSA in TBS containing 0.1 percent Tween 20 for 1 hour at room temperature. The
membranes were washed to remove the secondary antibody 3x for 5 minutes each with TBS
containing 0.1 percent Tween 20. To obtain results, the membrane was incubated with Super
Signal™ West Pico PLUS Chemiluminescent Substrate (34579, Thermofisher Scientific) for 5
minutes at room temperature. The blots were visualized under a CCD camera.

Table 4. Primary Antibodies Used for Western Blot.
Primary Antibody

Catalog Number/ Supplier

Anti-SREBP-1 Mouse Antibody (2A4)

sc-13551/ Santa Cruz

Anti β-Actin Rabbit Antibody (13E5)

4970/ Cell Signaling Technology

Table 5. Secondary Antibody Used for Western Blot.
Secondary Antibody

Catalog Number/Supplier

Anti-mouse IgG, HRP-linked Antibody

7076S/ Cell Signaling Technology

Anti-rabbit IgG, HRP-linked Antibody

7074S/ Cell Signaling Technology
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Chapter 3
Results
3.1 Insulin Mediated Expression of G6PDH

As the rate limiting enzyme in the pentose phosphate pathway, G6PDH is an important
enzyme in both carbohydrate and oxidation-reduction metabolism. Early studies on the
expression of the gene for G6PDH demonstrated regulation of its expression by diet and
hormones such as insulin (50, 51). Therefore, it is important to confirm that insulin induces the
expression of G6PDH in our model. Therefore, the effect of insulin on G6PDH expression was
evaluated by measuring G6PDH mRNA. We confirmed that insulin significantly induced the
expression of G6PDH compared to a no addition control as shown in Figure 3.
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Figure 3. Insulin Mediated Expression of G6PDH.
The change in expression of G6PDH was measured using the primer G6PD, Assay ID
Rn01529640_g1. Primary rat hepatocytes were incubated in low glucose media. 44nM insulin (I)
was added where indicated and incubated for 18 hrs. Values indicate fold increase in mRNA
compared to non-treated cells. The fold changed was expressed as the mean +/- S.E.(N=7).
Significance was evaluated using a One-way Anova test using Graphpad Prism.
**** Denotes significance of p<0.0001.

3.2 Insulin Mediated Expression of FAS

31

FAS is the 2nd committed step in fat synthesis and catalyzes the synthesis of fatty acids
from carbohydrates. Previous studies have shown that it is regulated primarily via changes in
nutritional status which can induce hormonal changes such as releasing insulin and glucagon (41,
44, 152, 153). Therefore, we wanted to confirm that insulin also induces FAS expression in our
system. The effect of insulin on FAS expression was evaluated by measuring FAS mRNA. We
confirmed that insulin significantly induced the expression of FAS compared to a no addition
control as shown in Figure 4.

Figure 4. Insulin Mediated Expression of FAS.
The change in expression of FAS was measured using the primer FASN, Assay ID
Rn00569117_m1. Primary rat hepatocytes were incubated in low glucose media. 44nM insulin
(I) was added where indicated and incubated for 18 hrs. Values indicate fold increase in mRNA
32

compared to non-treated cells. The fold changed was expressed as the mean +/- S.E.(N=7).
Significance was evaluated using a One-way Anova test using Graphpad Prism.
**Denotes significance of p<0.01.

3.3 Insulin Mediated Expression of SREBP1c
As previously discussed, the insulin induction of G6PDH and FAS expression via the
PI3K/Akt signal pathway is mediated through transcriptions factors. In evaluating those
transcription factors, we find that SREBP1c is the common transcription factor that is involved
in the insulin induction of both G6PDH and FAS. FAS and G6PDH both contain an SRE
element where SREBP1c would bind to allow the expression of the genes (40, 57). Therefore, it
is important to confirm that insulin induces the expression of SREBP1c in our system. The effect
of insulin on SREBP1c expression was evaluated by measuring SREBP1c mRNA. The results
shown in Figure 5 confirm that insulin significantly induced the expression of SREBP1c
compared to the no addition control.
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Figure 5. Insulin Mediated Expression of SREBP1c.
The change in expression of SREBP1c was measured using the primer SREBF1, Assay ID
Rn01495769_m1. Primary rat hepatocytes were incubated in low glucose media. 44nM insulin
(I) was added where indicated and incubated for 18 hrs. Values indicate fold increase in mRNA
compared to non-treated cells. The fold changed was expressed as the mean +/- S.E.(N=7).
Significance was evaluated using a One-way Anova test using Graphpad Prism.
** Denotes significance of p<0.01.

3.4 Insulin Mediated Suppression of INSIG2 Expression
INSIG2 is a very important protein that helps control lipogenesis via its ability to inhibit
SREBP1c processing (154). SREBP1c processing, is activated by insulin through 2 mechanisms;
one uses the mTOR pathway, and the other inhibits INSIG2 downstream of Akt independent of
the mTOR pathway (72). Insulin suppresses the expression of INSIG2 via the Akt pathway
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independent of the mTOR pathway which allows for the processing of SREBP1c. The processed
mature form of SREBP1c is then able to bind to promoter regions of target genes such as FAS
(20, 75). Therefore, it is important to confirm that insulin suppresses the expression of INSIG2 in
our system. We evaluated the insulin effect on INSIG2 expression and found that indeed insulin
significantly suppresses the expression of INSIG2 as measured by a decrease in its mRNA
compared to no addition control as shown in Figure 6.
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Figure 6. Insulin Mediated Suppression of INSIG2 Expression.
The change in expression of INSIG2 was measured using the primer INSIG2, Assay ID
Rn00710111_m1. Primary hepatocytes were incubated in low glucose media. 44nM insulin (I)
was added where indicated and incubated for 18 hrs. Values indicate fold increase in mRNA
compared to non-treated cells. The fold changed was expressed as the mean +/- S.E.(N=7).
Significance was evaluated using a One-way Anova test using Graphpad Prism.
**** Denotes significance of p<0.0001.
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3.5 Effect of Glucosamine on the Insulin Induction of G6PDH Expression

The expression of G6PDH and its activity is suppressed in metabolic diseases such as
Type I diabetes (155, 156). However, there are conflicting reports regarding its expression under
insulin resistant conditions. This may be in part due to the role of G6PDH in regulating oxidative
stress due to the production of NADPH, a reducing agent needed for the reduction of ROS (140,
157–162). Oxidative stress has been documented as a potential cause of insulin resistance (108,
129, 130, 163). Excessive production of NADPH can also lead to increased oxidative stress
therefore contributing to insulin resistance (157).
Previously, our laboratory has shown that insulin normalizes the expression of G6PDH in
Streptozotocin induced diabetic animals (142), and induces its expression via the mTOR
pathway in primary rat hepatocytes (55). Others have shown that this induction of G6PDH by
insulin is partially mediated through SREBP1c (56, 164, 165). Using a model of insulin
resistance induced by glucosamine, others in our lab have shown that the insulin induction of
G6PDH expression is suppressed (166). These results have been confirmed as shown in Figure 7.
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Figure 7. Insulin Mediated Expression of G6PDH in the Presence of Glucosamine.
Primary rat hepatocytes were incubated in low glucose media with or without glucosamine (G)
for 18 hrs. 44nM insulin (I) was added where indicated and incubated for 18 hrs. Values indicate
fold increase in mRNA compared to non-treated cells. The fold changed were expressed as the
mean +/- S.E. (N=7). Significance was evaluated using a One-way Anova test using Graphpad
Prism.
**** Denotes significance of p<0.0001.
*** Denotes significance of p<0.001.
* Denotes significance of p<0.05.
3.6 Effect of Glucosamine on the Insulin Induction of FAS.
Compounds other than glucosamine have been used to induce insulin resistance and their
effect on metabolism has been measured. For example, under palmitate induced insulin
resistance the insulin induction of fatty acid synthesis continues unabated (132, 137–139, 167).
Studies have shown that palmitate induces insulin resistance through two different mechanisms,
one through increasing flow in the HBP and the other by increasing oxidative stress (132, 168).
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Interestingly, oxidative stress also activates the HBP (116). Given that glucosamine induces
insulin resistance through bypassing the regulatory enzyme in HBP, it seems logical to conclude
that similar to palmitate induced insulin resistance, the induction of FAS expression by insulin
would continue unabated with glucosamine. Indeed, others in our lab evaluated this possibility
and showed that glucosamine does not affect the insulin induction of FAS expression (166) as
shown in Figure 8.
This indicates that under glucosamine induced insulin resistant conditions, there is one
mechanism that allows glucosamine to suppress the insulin induction of G6PDH expression
while another mechanism is allows the insulin induction of FAS to continue unabated.

Figure 8. Insulin Mediated Expression of FAS in the Presence of Glucosamine.
The change in expression of FAS was measured using the primer FASN, Assay ID
Rn00569117_m1. Primary rat hepatocytes were incubated in low glucose media with or without
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glucosamine (G) for 18 hrs.44nM insulin (I) was added where indicated and incubated for 18 hrs.
Values indicate fold increase in mRNA compared to non-treated cells. The fold changed were
expressed as the mean +/- S.E. (N=7). Significance was evaluated using a One-way Anova test
using Graphpad Prism.
**Denotes significance of p<0.01.
*Denotes significance of p<0.05.
ns Denotes no significance.

3.7 Glucosamine Effect on the Insulin Induced Expression of SREBP1c.

SREBP1c is a common transcription factor that mediates the insulin induction of both
FAS and G6PDH (29, 40). Others in our lab have shown that the insulin induction of SREBP1c
expression is suppressed under glucosamine induced insulin resistance (Ruff, 2015) and these
results are confirmed as shown in Figure 9. Since the insulin induced expression of SREBP1c is
suppressed with glucosamine similar to G6PDH, it suggests that a different mechanism that does
not involve SREBP1c is at work for FAS.
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Figure 9. Insulin Mediated Expression of SREBP1c in the Presence of Glucosamine.
Primary rat hepatocytes were incubated in low glucose media with or without glucosamine (G)
for 18 hrs.44nM insulin (I) was added where indicated and incubated for 18 hrs. Values indicate
fold increase in mRNA compared to non-treated cells. The fold changed were expressed as the
mean +/- S.E. (N=7). Significance was evaluated using a One-way Anova test using Graphpad
Prism.
**Denotes significance of p<0.01.
*Denotes significance of p<0.05.
ns Denotes no significance.

3.8 Glucosamine Effect on the Insulin Induced Suppression of INSIG2 Expression.
As discussed earlier, INSIG2 is an inhibitor of SREBP1c processing (154). The
expression of INSIG2 is suppressed by insulin in an Akt dependent manner (20). Others have
shown in our lab that glucosamine suppresses the insulin induced phosphorylation of Akt. With
INSIG2, downstream of Akt, it is safe to conclude that glucosamine suppresses the insulin effect
on INSIG2 expression. Therefore, the effect of glucosamine on the insulin induced suppression
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of INSIG2 expression was evaluated and as shown in Figure 10, surprisingly, glucosamine did
not have a significant effect on the insulin induced suppression of INSIG2 expression. With
these results similar to the FAS results, it would suggest that the mechanism that glucosamine
uses to allow the insulin effect of FAS and INSIG2 expression to continue is the same. These
results would also suggest that that under glucosamine induced insulin resistance, any available
SREBP1c will be processed.

Figure 10. Insulin Mediated Suppression of INSIG2 Expression in the Presence of Glucosamine.
The change in expression of INSIG2 was measured using the primer INSIG2, Assay ID
Rn00710111_m1. Primary hepatocytes were incubated in low glucose media with or without
glucosamine (G) for 18 hrs.44n insulin (I) was added where indicated and incubated for 18 hrs.
Values indicate fold increase in mRNA compared to non-treated cells. The fold changed were
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expressed as the mean +/- S.E. (N=7). Significance was evaluated using a One-way Anova test
using Graphpad Prism.
****Denotes significance of p<0.0001.
** Denotes significance of p <0.01.
ns Denotes no significance.

3.9 Effect of LXRα Agonist on the Insulin Induction of G6PDH Expression with or without
Glucosamine
Given that glucosamine differentially effected the insulin induction of G6PDH and FAS
expression and that the effect of glucosamine on the insulin induction of SREBP1c expression
mirrored the effect of G6PDH, suggests that other factor(s) beyond SREBP1c is involved in
maintaining the insulin induction of FAS expression with glucosamine. Thus, the promoter
regions for both FAS and G6PDH were evaluated for a possible clue to explain this difference.
We found that besides both genes containing a binding site for SREBP1c, they both contain a
site for USF while only the FAS promoter contains a binding site for LXR (40, 57).
LXR is a transcription factor that is involved in the regulation of lipogenesis and
cholesterol synthesis. LXRα is highly expressed in the liver and has been shown to induce the
expression of lipogenic genes such as FAS and SREBP1c (40).
LXRα agonist effect on insulin resistance by other compounds was evaluated to offer a
clue about the possibility of LXR being the differentiator in the regulation of gene expression of
G6PDH and FAS under glucosamine induced insulin resistance. We found that LXRα through its
agonist is able to overcome the insulin resistant effect of fat by inhibiting oxidative stress (132).
Interestingly HBP is also activated by oxidative stress. With glucosamine bypassing the
committed step in HBP to induce insulin resistance, it makes sense to conclude that LXRα would
also overcome the glucosamine effect on the insulin induction of G6PDH.Therefore, we
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evaluated whether LXRα through its agonist is able to overcome the glucosamine effect on the
insulin induction of G6PDH. We found that LXRα agonist did not affect the basal expression of
G6PDH compared to the no addition control, nor did it effect the insulin induction of G6PDH.
LXRα agonist also did not affect the glucosamine effect on the insulin induction of G6PDH
expression or the basal expression with glucosamine as shown in Figure 11.
This indicates that unlike with palmitate, LXRα agonist was not able to overcome the
glucosamine effect on the insulin induction of G6PDH. With G6PDH not containing an LXRE to
allow LXR to bind to its promoter, it might be possible, that the presence of an LXRE on the
promoter of the target gene is a key for LXRα through its agonist to overcome the insulin
resistant effect on the target gene.
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Figure 11. Insulin Mediated Expression of G6PDH in the Presence of Glucosamine and LXR
Agonist TO901317.
The expression of G6PDH was measured using the primer G6PD, Assay ID Rn01529640_g1.
Primary rat hepatocytes were incubated in low glucose media with or without glucosamine (G)
for 18 hrs.44nM insulin (I) was added where indicated and incubated for 18 hrs.1uM LXR
agonist TO901317 (T) was added where indicated and incubated for 18 hrs. Values indicate fold
increase in mRNA compared to non-treated cells. DMSO was used as a negative control. The
fold changed were expressed as the mean +/- S.E. (N=7). Significance was evaluated using a
One-way Anova test using Graphpad Prism.
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**** Denotes significance of p<0.0001
*** Denotes significance of p<0.001
**Denotes significance of p<0.01.
*Denotes significance of p<0.05.
ns Denotes no significance.

3.10 Effect of LXRα Agonist on the Insulin Induction of FAS Expression with or without
Glucosamine
FAS as discussed above contains of LXRE element to allow LXRα to bind to its promoter
region. Others have shown that LXRα through its agonist induces the expression of FAS
independent of SREBP1c processing. Glucosamine did not have an effect on the insulin
induction of FAS expression. Glucosamine also activates LXRα via glycosylation (85, 89).
Therefore, it becomes possible that LXRα is the mediator in the mechanism that allows
glucosamine to work to allow the insulin induction of FAS to continue unabated.

Therefore, we evaluated the LXRα agonist effect on the insulin induction of FAS
expression. We found as indicated in Figure 12 that LXRα agonist indeed significantly induced
the expression of FAS compared to no addition control. There was also an insulin additive effect
on the LXRα induction of FAS. Glucosamine did not affect the LXRα agonist induction of FAS
expression alone and with insulin. This indicates that LXRα might be the mediator in the
mechanism that glucosamine uses to allow the insulin induction of FAS to continue
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Figure 12. Insulin Mediated Expression of FAS in the Presence of Glucosamine and LXR
Agonist TO901317.
The change in expression of FAS was measured using the primer FASN, Assay ID
Rn00569117_m1. Primary hepatocytes were incubated in low glucose media with or without
glucosamine (G) for 18 hrs. 44nM insulin (I) was added where indicated and incubated for 18
hrs.1uM LXR agonist TO901317 (T) was added where indicated and incubated for 18 hrs.
Values indicate fold increase in mRNA compared to non-treated cells. DMSO was used as a
negative control. The fold changed were expressed as the mean +/- S.E. (N=7). Significance was
evaluated using a One-way Anova test using Graphpad Prism.
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ns Denotes non significance.
*** Denotes significance of p<0.001.
** Denotes significance of p <0.01.
*Denotes significance of p<0.05.
ns Denotes no significance.

3.11 LXRα Agonist Effect on the Insulin Induction of SREBP1c Expression with or without
Glucosamine
SREBP1c contains an LXRE on its promoter region for LXR binding (69). Under fat
induced insulin resistance, SREBP1c expression was elevated with LXRα agonist (132). As
discussed above, there is also evidence that palmitate induced insulin resistance induces the HBP.
Glucosamine induces insulin resistance via bypassing the committed step in the HBP. Therefore,
it is logical to say that LXRα agonist overcomes the glucosamine induced insulin resistance on
SREBP1c. Therefore, we evaluated the LXRα agonist effect on the glucosamine effect on the
insulin induction of SREBP1c expression.
As shown in Figure 13, we confirmed that LXRα agonist significantly induced the expression of
SREBP1c compared to no addition control. There also is an insulin additive effect on the LXRα
induction of SREBP1c expression. Glucosamine however, significantly suppressed the LXRα
induction of SREBP1c expression alone and with insulin. These results further solidify the
possibility that the mechanism that glucosamine uses to work on FAS is not through SREBP1c.
This also indicates that in contrast with FAS, and similar to G6PDH, the other mechanism that
glucosamine uses to suppress the insulin induction of SREBP1c is not affected by LXRα agonist.
This further solidifies the possibility of glucosamine working on FAS through LXR to allow the
insulin induction of FAS expression to continue.
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Figure 13. Insulin Mediated Expression of SREBP1c in the Presence of Glucosamine and LXR
Agonist TO901317.
The change in expression of Srebp1c was measured using the primer Srebf1, Assay ID
Rn01495769_m1. Primary rat hepatocytes were incubated in low glucose media with or without
glucosamine (G) for 18 hrs. 44nM insulin (I) was added where indicated and incubated for 18
hrs.1uM LXR agonist TO901317 (T) was added where indicated and incubated for 18 hrs.
Values indicate fold increase in mRNA compared to non-treated cells. DMSO was used as a
negative control. The fold changed were expressed as the mean +/- S.E. (N=7). Significance was
evaluated using a One-way Anova test using Graphpad Prism.
*** Denotes significance of p<0.001.
** Denotes significance of p <0.01.
*Denotes significance of p<0.05.
ns Denotes no significance.
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3.12 Effect of LXRα Agonist on the Insulin Induced Suppression of INSIG2 with or without
Glucosamine
According to our results in Figure 13, we found that that compared to no addition control,
LXRα agonist still significantly induced the expression of SREBP1c.We also found according to
our results in Figure 11, glucosamine did not affect the insulin induced suppression of INSIG2,
an inhibitor of SREBP1c processing. In evaluating the LXRα agonist on SREBP1c processing,
some have shown that LXRα agonist inhibits SREBP1c processing which is correlated with an
increase in INSIG2 mRNA and protein in mice livers and rat hepatocytes (42, 87). In culture, it
has also been shown that LXRα through its agonist does not have an effect on the insulin induced
suppression of INSIG2 (87). Others have shown that low concentrations of LXRα agonist
elevated SREBP1c processing in mice livers of high fat fed mice (169). With the glucosamine
effect on the insulin induced suppression of INSIG2 expression similar to FAS, it becomes
possible that LXRα agonist might not affect the insulin effect on INSIG2. Therefore, we
evaluated the LXRα agonist effect on the insulin effect on INSIG2. We found that according to
Figure 14, that LXRα agonist did not affect the basal expression of INSIG2 compared to no
addition control, nor did it effect the insulin induced suppression of INSIG2 expression. LXRα
agonist did not alter the basal expression of INSIG2 expression with glucosamine, nor did it
effect the insulin induced suppression of INSIG2 with glucosamine. This indicates that LXRα
does not have an effect on the insulin induced suppression of INSIG2 under normal or
glucosamine induced insulin resistance.
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Figure 14. Insulin Mediated Expression of INSIG2 in the Presence of Glucosamine and LXR
Agonist TO901317.
The change in expression of INSIG2 was measured using the primer INSIG2, Assay ID
Rn00710111_m1. Primary rat hepatocytes were incubated in low glucose media with or without
glucosamine (G) for 18 hrs. 44nM insulin (I) was added where indicated and incubated for 18
hrs.1uM LXR agonist TO901317 (T) was added where indicated and incubated for 18 hrs.
Values indicate fold increase in mRNA compared to non-treated cells. DMSO was used as a
negative control. The fold changed were expressed as the mean +/- S.E. (N=7) Significance was
evaluated using a One-way Anova test using Graphpad Prism.
**** Denotes significance of p<0.0001.
*** Denotes significance of p <0.001.
**Denotes significance of p<0.01
ns Denotes no significance.
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3.13 Effect of LXRα Agonist on SREBP1c Processing with or without Glucosamine
Our results in Figure 13 show that LXRα though its agonist still significantly induces the
expression of SREBP1c compared to no addition control. Our results in Figure 14 also show that
LXRα did not affect INSIG2 expression, nor did it effect the insulin effect on INSIG2 expression
with or without glucosamine. Therefore, it becomes logical to say that LXRα through its agonist
might not affect SREBP1c processing. Therefore, we evaluated the LXRα agonist effect on
SREBP1c processing, and found as show in Figure 15 that similar to SREBP1c expression,
LXRα significantly increases the amount of precursor SREBP1c protein compared to no addition
control, and that glucosamine significantly reduces it. There was also a significantly increased
amount of mature SREBP1c as a result of LXRα agonist inducing high amounts of precursor
SREBP1c, however glucosamine did not have an effect on the amount of mature SREBP1c
protein induced by LXRα. This indicates that LXRα might not have an effect on SREBP1c
processing. These results along with the results from the LXRα agonist effect on INSIG2
expression would solidify that whatever pSREBP1c is available to be processed will be
processed.
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Figure 15. Effect of LXRα Agonist on SREBP1c Processing.
Western blots were used to measure the amount of Srebp1c protein, the antibody used to detect
SREBp1c was anti-SREBP1c mouse 2A-4 (sc-13551, Santa Cruz) and the antibody for betaactin was anti β-actin rabbit (13E5) (4970, Cell Signaling Technology). Primary rat hepatocytes
were incubated in low glucose media with or without glucosamine (G) for 18 hrs. 44nM insulin
(I) was added where indicated and incubated for 18 hrs.1uM LXR agonist TO901317 (T) was
added where indicated and incubated for 18 hrs. DMSO was used as a negative control.
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Chapter 4
Discussion
Lipogenesis is an important complex metabolic process that allows for the conversion of
excess carbohydrates to triglycerides (TG) that are stored mainly in the liver and adipose tissues.
The process starts with converting acetyl CoA, an intermediate metabolite from glycolysis and
other metabolic pathways to the 16-carbon fatty acid chain, palmitate. Palmitate then undergoes
desaturation and esterification to become triglycerides. The amount of fat accumulation is
determined by the balance between fatty acid synthesis and fatty acid oxidation (170). Therefore,
any dysregulation due to obesity, type 2 diabetes or oxidative stress can lead to excessive fat
accumulation which results in non-alcoholic fatty liver disease (NAFLD). NALFD can range from
excess fatty liver, to hepatic steatosis to liver cirrhosis due to excess fat from lipolysis in the
adipose tissues, to excess lipogenesis, and decreased fatty acid oxidation (134, 135). The
complications from NALFD including obesity and cardiovascular issues have heightened the
importance of understanding how lipogenesis is regulated and what happens when dysregulation
occurs.
The rate of lipogenesis is determined by two key lipogenic enzymes that catalyze the
committed steps of this metabolic pathway, ACC which catalyzes the 1st committed step and FAS
which catalyzes the 2nd committed step of fatty acid synthesis. ACC is a complex molecule that
catalyzes the formation of malonyl CoA from acetyl CoA. The catalytic site of the complex
molecule contains 2 catalytic sites, the first one is a biotin carboxylase site at which biotin, a
required cofactor, is carboxylated, the second one is a carboxylase site that transfers the
carboxylate group to acetyl CoA to form malonyl CoA (171, 172). FAS is a multicomplex
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homodimeric enzyme that catalyzes the second committed step of fatty acid synthesis. The FAS
monomer contains six catalytic sites which are beta-ketoacyl synthase (KS), acetyl/malonyl
transacylase (AT/MT), beta-hydroxyacyl dehydratase (DH), enoyl reductase (ER), beta-ketoacyl
reductase (KR), acyl carrier protein (ACP), and thioesterase (TE) that sequentially aid in the
synthesis of the 16-carbon chain palmitate from acetyl CoA and malonyl CoA (173, 174).
Like other metabolic pathways, lipogenesis is regulated by the nutritional and hormonal
status. During fasting conditions, circulating glucose is low and glucagon levels are high which
lead to inhibition of lipogenesis and the stimulation of fatty acid oxidation. Under feeding
conditions however, circulating glucose and insulin levels are high which leads to the induction of
lipogenesis and the inhibition of fatty acid oxidation. Insulin activation is stimulated through
specific signaling pathways such as the PI3K pathway and downstream signal molecules such as
Akt, the atypical protein kinase C (aPKC), and the mTOR pathway, as well protein phosphatases
such as PP1 and PP2 (41, 175–180).
Glucose and insulin both regulate the lipogenic enzymes through changes in gene
expression and posttranslational modifications such as phosphorylation and dephosphorylation of
the enzymes themselves. For example, insulin and glucose activate ACC by dephosphorylation by
PP1 in many cell types such as beta cells, hepatocytes, and adipocytes (24, 181–185). Insulin and
glucose also regulate the gene expression of FAS and ACC via the mTOR pathway and PP1 which
control the expression and activity of the transcription factors on the promoter regions of both
genes (40, 158, 166–169).
PPP is another important metabolic pathway that is regulated by insulin, diet, and oxidative
stress. The role of this pathway is to produce NAPDH, a cofactor needed for the synthesis of fatty
acids and to combat oxidative stress. It also has a role to produce the ribose-5-phosphate needed
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for nucleic acid synthesis. The rate of glucose flux into the PPP is controlled by G6PDH, the
enzyme that catalyzes the 1st committed step. G6PDH, first discovered in 1931, is a protein that is
active in dimer or tetramer form due to G6P and NADP binding to it (29). Like other metabolic
pathways, the regulation of the PPP is tightly controlled and flux through the pathway can vary
due to the nutritional and hormonal status, and oxidative stress (29).
Earlier studies in whole animals and cells in culture have shown that under fasting
conditions or low glucose and insulin conditions the activity and expression levels of G6PDH was
reduced. While under feeding conditions, in response to insulin and glucose, the activity and
expression levels of G6PDH were elevated (55, 142, 190, 191). Insulin induces the expression of
G6PDH in hepatocytes via the mTOR pathway downstream of the PI3K/Akt pathway (55).
The transcriptional regulation of lipogenic genes has been a focus of study for many years
(20, 40, 45, 65, 70, 84, 192–194). It has been shown that the insulin regulation of lipogenic genes
involves the changes in gene expression and posttranslational modifications of the transcription
factors ChREBP, SREBP1c, LXR, and USF (40, 195). SREBPs are bHLH-LZ transcription factors
that bind as dimers to the sterol regulatory elements (SRE) of the promoter regions of target genes
involved in metabolic pathways. There are 3 isoforms of SREBPs which are SREBP1a, SREBP1c,
and SREBP2, with SREBP1c being most predominately expressed in the liver and responsible for
the regulation of the expression of lipogenic genes (192). Overexpression studies of SREBP1c in
fasted mice and knockout studies of SREBP1c in refed mice demonstrated that SREBP1c is a key
transcription factor for the induction of lipogenic genes (196). Cell culture studies have shown a
role of SREBP1c in the insulin induction of FAS and G6PDH, the 2 metabolic genes included in
this study (29, 180, 197).
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The activity of SREBP1c on its target genes requires the proteolytic processing of the
enzyme. The protein is synthesized in an inactive form which is located at the ER as a larger
complex with SCAP and INSIG proteins (72). SCAP proteins are ER sterol sensor proteins that
escalate SREBPs from the ER to golgi by binding with the COPII vesicles of the golgi. INSIG are
proteins when highly expressed are bound to the SCAP to prevent its binding to the COPII vesicles
of the golgi. Once SREBP1c is cleaved, the mature N-terminal SREBP1c is translocated to the
nucleus where it can now bind to the SRE elements of its target genes. Insulin induces the
proteolytic processing of SREBP1c via 2 different pathways downstream of Akt to induce FAS
expression (74, 75, 95). One pathway involves the insulin suppression of INSIG2 gene expression
independent of the mTOR pathway. The other pathway involves the P70 S6 kinase downstream of
the mTOR pathway. P70 S6 kinase is a serine threonine kinase that is part of the mTOR pathway
that is downstream of PI3K. It is involved in many processes such as metabolism, cell growth and
survival (198).
Over the years it has been established that glucosamine, a molecule that bypasses GFAT
and activates HBP, induces insulin resistance in various cell types and whole animals.
Glucosamine induces insulin resistance by lowering insulin sensitivity by reducing IRS-1 tyrosine
phosphorylation. This decrease in active IRS-1 leads to the reduction of the PI3K/Akt signaling
pathway along with the reduction of the insulin induced activation of the mTOR pathway
downstream of Akt, which then leads to decreased glucose tolerance (102, 104, 107, 199). OGT,
the key enzyme in O-glycosylation of proteins, was shown to play a key role in inducing insulin
resistance through its overexpression in vivo in mice (103). Glucosamine was also able to elevate
FAS and ACC gene expression in adipocytes (200). However, others in our lab have seen little
effect of glucosamine on the expression of FAS in rat hepatocytes (166).
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Our laboratory utilized glucosamine to establish an insulin resistant model in primary rat
hepatocytes in culture to study G6PDH, the key enzyme in regulating the glucose shunt through
PPP, and FAS, the key enzyme in the regulation of fatty acid synthesis from excess glucose. Others
in our lab have evaluated the effect of glucosamine on the insulin induction of G6PDH and FAS.
They found as expected that glucosamine would suppress the insulin induction of G6PDH
expression. Surprisingly though, they found that glucosamine did not affect the insulin induction
of FAS even though insulin regulation of both FAS and G6PDH is mediated through the PI3K/Akt
pathway. Others in our lab have shown in hepatocytes that glucosamine suppresses the insulin
induction of Akt phosphorylation at Ser473. These results suggest a possible mechanism to disrupt
the insulin signal pathway since for insulin to fully activate the PI3K/Akt pathway, Akt must be
phosphorylated by PDK-1, which allows the mTORC2 to phosphorylate Akt at Ser473. Others
have shown in adipocytes that the insulin induction of Akt phosphorylation at Thr308 was
suppressed by glucosamine (201). Although our laboratory had not investigated the
phosphorylation status of Thr308 on the Akt protein with glucosamine, it is anticipated that results
similar to those found in adipocytes could also be found. Since our results support the findings that
glucosamine affects the PI3K/Akt pathway it suggests that there must be a different mechanism
not involving this pathway to keep the insulin induction of FAS expression unabated with
glucosamine.
To evaluate which mechanism glucosamine utilizes to manifest the effects on FAS
expression, the transcription factors involved in the insulin induction of G6PDH, and FAS
expression must be evaluated. From the literature, it is known that insulin induces the expression
of G6PDH via SREBP1c binding to the SRE of the promoter of G6PDH. G6PDH contains a
binding site for USF similar to FAS but the role of this site has yet to be determined. The binding
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site for USF in FAS is required for SREBP1c to be recruited to the SRE element during the insulin
induction of FAS expression (202). The insulin induction of SREBP1c requires the cooperation of
LXR, SREBP1c, NF-Y, and SP1 to fully induce the expression of SREBP1c downstream of the
mTOR pathway (66). G6PDH also contains several SP1 binding sites, but none have been shown
to be involved in the insulin induction of G6PDH to date (57). Under refeeding conditions, LXRα
agonist can induce the expression of FAS independent SREBP1c (42), an indication that LXR can
induce the expression of FAS independent of SREBP1c.
Since SREBP1c is part of the mechanism by which both G6PDH and FAS are induced by
insulin suggests that it might not be part of the mechanism through which glucosamine exerts it
effect in hepatocytes. This assumption is substantiated by our results that show that similar to
G6PDH glucosamine did suppress the insulin induction SREBP1c expression. Some other
mechanism must be in play for FAS since induction of its expression by insulin was not suppressed
by glucosamine.
In addition to insulin inducing the expression of SREBP1c, insulin also induces the
processing of SREBP1c in an Akt dependent manner (20, 72). SREBP1c processing is required
for the SREBP1c to bind to the SRE element of its target gene. INSIG2 has been shown to inhibit
SREBP1c processing by keeping it bound to the ER in a complex with SCAP. When insulin
suppresses the expression of INSIG2, the amount of INSIG2 protein also is reduced leading to the
dissociation of the pSREBP1c from the ER to initiate the processing of SREBP1c. The insulin
suppression of INSIG2 happens in an Akt dependent but mTOR independent mechanism. As
discussed above, glucosamine suppresses the phosphorylation of Akt induced by insulin.
Therefore, one would expect that glucosamine would minimize the insulin induced suppression of
INSIG2 expression. Surprisingly however, we found that glucosamine did not have an effect on
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the insulin suppression of INSIG2. Therefore, similar to FAS expression, glucosamine utilizes a
different mechanism to allow the insulin suppression on INSIG2 suppression to continue. Since
glucosamine reduces the insulin induced phosphorylation and activation of Akt, it seems plausible
that the Akt pathway must be important in the glucosamine suppression of the insulin induction of
G6PDH. Also, since glucosamine does not suppress the insulin induction of FAS, another
mechanism or pathway must be involved. In reviewing the literature and evaluating other possible
mechanisms, it was found that insulin induced suppression of INSIG2 down stream of Akt is
mediated by CREBZF in liver cells of mice (203). CREB/ATF bZIP transcription factor
(CREBZF) is a co repressor that inhibits the cAMP mediated transcription of cAMP responsive
genes such as INSIG2 (203).This study also showed that under fat induced insulin resistance, the
expression of CREBZF is elevated in livers of high carbohydrate/ high fat mice (203). Although
no studies to date have linked CREBZF to glycosylation or glucosamine, it is interesting to
speculate that glucosamine induced insulin resistance might influence the expression of CREBZF.
With SREBP1c possibly not involved in the mechanism that allows the insulin induction
of FAS to continue in the presence of glucosamine, our attention turned to another transcription
factor that is involved in the regulation of FAS and SREBP1c which is LXR. LXR is a transcription
factor that is involved in the insulin induction of FAS (204). It is a transcription factor that belongs
to the nuclear hormone receptor superfamily of the sterol regulated transcription factors that are
activated by ligands binding to them such as oxysterols (40). It has been shown before that LXR
is a key transcription factor downstream of Akt that is involved in the insulin induction of FAS
and SREBP1c (53). LXR is downstream of S6K1 of the mTOR pathway and has been shown to
be activated under palmitate induced insulin resistance (167). In the presence of palmitate, the
protein expression levels of mTOR, S6K1, LXRα, SREBP-1c, FAS, ACC1 and phosphorylated
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mTOR, S6K1, and mRNA expression levels of lipogenesis-related markers were significantly
upregulated in a time-dependent manner demonstrating that palmitate-induced lipid accumulation
is associated with the increase in both mTOR/S6K1 and LXRα levels via the upregulation of
downstream lipogenic genes.
LXRα through its agonist has been shown to overcome fat induced insulin resistance and
its effect on gluconeogenesis without effecting fatty acid synthesis, as indicated by constant TG
synthesis, (132) by preventing oxidative stress which inhibits the JNK pathway, a pathway that
inhibits the insulin induced activation of the PI3K/Akt pathway in obese mice (132). This
inhibition leads to the restoration of the insulin induction of Akt phosphorylation at Ser473 (132).
In the same study, the insulin induction of SREBP1c is not affected in obese mice possibly due to
the activation of the mTOR pathway independent of Akt activation in these animals. This
conclusion is supported by a study that shows that in culture, palmitate, a molecule that mimics fat
induced insulin resistance, induces SREBP1c expression and subsequently FAS expression (167).
With oxidative stress activating the HBP and LXRα agonist inhibiting oxidative stress to
restore Akt phosphorylation at Ser473, one might question whether LXRα overcomes the
glucosamine effect on the insulin induction of G6PDH and SREBP1c. Interestingly, our results
show that LXRα did not overcome the glucosamine effect on the insulin induction of both G6PDH
and SREBP1c. Moreover, glucosamine also suppressed the LXRα induction of SREBP1c
expression. This is an indication that oxidative stress might not be involved in the glucosamine
effect on the induction of SREBP1c expression by both LXR and insulin and on the insulin
induction of G6PDH expression. Others in our lab have shown using the JNK inhibitor SP600125,
that inhibiting that the JNK pathway, a pathway activated by oxidative stress, did not ameliorate
the glucosamine effect on G6PDH and SREBP1c expression nor did it change the expression of
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FAS expression when glucosamine was added, supporting the conclusion that oxidative stress is
not a mediator in these findings. In evaluating the mechanisms that regulate LXRα in the literature,
it was shown that AMPK which is activated by glucosamine suppresses the LXRα agonist
induction of SREBP1c in rat hepatoma cells (205, 206). So, it is possible that glucosamine could
activate the AMPK protein thereby reducing the LXRα induction of SREBP1c expression
Since inhibiting the JNK pathway did not change the insulin induction of FAS when
glucosamine was added, other mechanism(s) must be involved. We showed in this study that
glucosamine did not affect the LXRα agonist induction of FAS alone or with insulin, which is a
different outcome than what happened with SREBP1c. With both promoter regions containing an
LXRE, this would indicate that other factors beyond LXR binding to the target gene are involved
in the glucosamine effect on the metabolic genes if glucosamine acts on FAS via LXRα. In
examining those factors, one of proteins involved in the regulation of a FAS and G6PDH is
INSIG2. INSIG2 as discussed above, is an inhibitor of SREBP1c processing.
Our results show that glucosamine does not affect the insulin induced suppression of
INSIG2 similar to the no effect of glucosamine on the insulin induction of FAS. Therefore, it
becomes important to understand whether LXRα agonist has a similar effect on INSIG2. Others
have shown that LXRα agonist elevated the expression of INSIG2 correlated with a decrease in
SREBP1c, however when insulin was present the agonist did not overcome the suppression of
INSIG2 expression. Therefore, LXRα does not affect the insulin action on INSIG2 (42, 87).
Another study showed that the under high fat diet, the LXRα agonist still elevated SREBP1c
processing (169). In our study, the LXRα agonist did not affect the expression of INSIG2 alone or
the insulin effect on INSIG2 with or without glucosamine.
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In examining the regulation of INSIG2 by other factors, it has been shown that glucagon
activates INSIG2 to inhibit lipogenesis by shutting down SREBP1c processing (194, 207). AMPK,
which is inhibited by insulin also activates INSIG2 expression and protein activity (208). AMPK
increases LXRα expression and protein levels in macrophages while other studies have shown
AMPK decreases the LXR induced expression of SREBP1c correlated with decreased nSREBP1c
(91, 205). With glucosamine activating AMPK pathway (206, 209), we would expect an increase
in INSIG2 expression with glucosamine, but there was no effect on the basal expression of INSIG2
in our study.
With LXRα agonist not affecting INSIG2 expression, we would expect similar outcome
with SREBP1c processing. We found that the protein amounts of nSREBP1c induced by LXRα
agonist was not affected by glucosamine despite a reduction in the amount of pSREBP1c induced
by LXRα agonist. These results correlate with the SREBP1c expression being reduced by
glucosamine, and the INSIG2 expression not effected by glucosamine. So, processing of available
SREBP1c might is not impacted by glucosamine. Therefore, whatever SREBP1c is available will
be processed. These results further support the possibility that SREBP1c is not involved in the
mechanism that allows glucosamine to work on FAS expression.
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Chapter 5
Conclusion and Significance

The goal of this study was to examine the insulin resistant effect on the insulin regulation
of two important metabolic genes, FAS and G6PDH. We utilized glucosamine as an insulin
resistant model due to many studies that show that excess glucose causes higher flux through the
HBP which causes insulin resistance. In this study, we focused on the regulation of the gene
expression of G6PDH and FAS under glucosamine induced insulin resistant conditions. These
enzymes that are important in the regulation of PPP and fatty acid synthesis respectively, two
important pathways in maintaining glucose homeostasis. We concluded that glucosamine
suppressed the insulin induction of G6PDH expression, while it did not affect the insulin
induction of FAS expression. SREBP1c, a common transcription factor that is involved in the
insulin induction of both G6PDH and FAS expression, was also suppressed by glucosamine. The
insulin induced suppression of INSIG2 expression, a protein that inhibits SREBP1c processing,
was not affected by glucosamine. With LXRα being a transcription factor involved in the
regulation of SREBP1c and FAS expression, we evaluated its effects on our target molecules
using a LXRα agonist, TO901317. We concluded that the LXRα agonist did not have an effect
on the basal expression of G6PDH, nor the insulin induction of G6PDH expression. LXRα
agonist also did not have an effect on either the basal expression or the insulin induction of
G6PDH expression in the presence of glucosamine. Interestingly, the LXRα agonist alone
increased the basal expression of FAS and this increase appears to be additive with insulin.
Glucosamine did not influence the LXRα agonist induction of FAS expression alone or with
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insulin, an indication that glucosamine might utilize LXRα to allow the insulin induction of FAS
to continue. Similar to FAS, LXRα agonist induces the basal expression of SREBP1c, and
insulin has an additive effect on this induction. Although glucosamine significantly suppressed
the LXRα agonist effect on SREBP1c expression alone and with insulin, the level of SREBP1c
expression was still higher than baseline indicating a significant amount of SREBP1c was
available for processing. These results tend to suggest that SREBP1c might not be the
differentiator in the regulation of G6PDH and FAS under glucosamine induced insulin
resistance.
To uncover whether SREBP1c was processed to its mature form under these
experimental conditions, we evaluated the expression of INSIG2 which is an inhibitor of
SREBP1c processing. LXRα agonist did not have an effect on the basal expression of INISIG2,
nor the insulin induced suppression of INSIG2 expression, and these expression levels were
unaltered in the presence of glucosamine. The results suggest that under our experimental
conditions with LXRα agonist any available SREBP1c could be processed to its mature form.
Western blot analysis confirmed that the precursor form of SREBP1c induced by LXRα agonist
continued to be processed to the mature form. These results support the conclusion that
glucosamine regulates the insulin induced expression G6PDH and FAS via two different
mechanisms. The first mechanism involves glucosamine reducing the insulin induction of
G6PDH expression by reducing the expression of SREBP1c. The second mechanism involves
glucosamine acting via LXRα to allow the insulin induction of FAS expression to continue
despite lower pSREBP1c protein levels.
Our study is important to help understand the mechanism of insulin resistance which can
lead to finding additional possible treatments for diabetes. In other models of insulin resistance
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such as palmitate induced insulin resistance, it is well documented that the insulin induction of
fatty acid synthesis, based on continuation of normal TG values, continues unabated. This model
mimics fat induced insulin resistance. While fatty acid synthesis under these conditions
continues unabated, other pathways such as the insulin induced inhibition of gluconeogenesis is
suppressed leading to an imbalance in glucose homeostasis that leads to higher blood sugar.
The higher blood sugar which is a characteristic of diabetes results in many
complications such as eye, nerve, and renal damage. Therefore, it is very important to understand
all aspects of this disease. Our study focuses on the glucosamine effect on the insulin regulation
of FAS and G6PDH, key enzymes in carbohydrate metabolism and fat synthesis to help better
understand mechanisms of diabetes that may lead to additional treatments for the disease. In our
study, we found that glucosamine suppresses the insulin induction of SREBP1c, a common
transcription factor involved in the insulin induction of both G6PDH and FAS expression. This is
a significant variance from other models of insulin resistance that show that the insulin induction
of SREBP1c is not affected by insulin resistance. The suppression of the insulin induction of
SREBP1c by glucosamine would mean that the insulin induction of FAS and G6PDH expression
should be suppressed by glucosamine. However, in our model, the insulin induction of FAS
expression is not affected by glucosamine, unlike the insulin induction of G6PDH expression
which is suppressed by glucosamine similar to SREBP1c. So, we addressed how would
glucosamine allow the insulin induction of FAS to continue even though SREBP1c expression is
reduced. Could it be possible that glucosamine modulates other transcription factors? Other
common factors include USF which is required for the insulin induction of FAS by recruiting
SREBP1c, and ChREBP which has been shown to regulate FAS expression in response to
glucose (40, 57). ChREBP and USF has not been linked to the regulation of G6PDH expression
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yet. Therefore, USF and ChREBP regulation of G6PDH can be evaluated in future studies.
LXRα is an important transcription factor in the regulation of the insulin induction of FAS and
SREBP1c expression but not for G6PDH, so our efforts focused on this protein. Although, we
found that glucosamine suppresses the LXRα induction of SREBP1c alone and with insulin,
there was still a significant amount of SREPB1c being expressed under these conditions.
Glucosamine, however, had no effect on the LXRα agonist induction on FAS expression alone or
with insulin. This is a significant outcome because other models of insulin resistance show that
the induction of SREBP1c expression is correlated to the induction of fatty acid synthesis.
Results from others show that the insulin induction of FAS requires USF to recruit SREBP1c to
the promoter, therefore USF is necessary to stimulate the insulin induction of FAS via SREBP1c
(193, 202, 210). To confirm that in our system, we would need to evaluate whether insulin
induces the binding of SREBP1c and USF to the promoter regions of FAS by first showing that
insulin induces the binding of SREBP1c to the promoter region of FAS. Since USF binding to
the promoter region of FAS does not change in response to insulin, then we will need to evaluate
the SREBP1c-USF binding in response to insulin. Since insulin phosphorylates USF via DNAPK, then the insulin induced phosphorylation of USF would need to be evaluated.
LXRα agonist induction of SREBP1c expression is still significant under glucosamine
induced insulin resistance. Western blot analysis demonstrated that in cells treated with the
LXRα agonist, SREBP1c processing is not affected with or without glucosamine. The insulin
induced suppression of INSIG2 expression was also not affected under the same conditions.
Also, in our study, glucosamine suppresses the insulin induction of SREBP1c to near basal levels
suggesting that another mechanism is in play that can bypass SREBP1c and allow the insulin
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induced expression of FAS to continue. This maybe through the LXRα because LXRα is
required for the insulin induction of FAS (204).
With SREBP1c still significantly expressed by LXRα despite the suppressive effects of
glucosamine, and the processing of SREBP1c not impacted under these conditions, the question
arises as to whether the insulin induction of USF/SREBP1c binding also suppressed by
glucosamine? If that is the case, then that further supports that glucosamine uses a mechanism
that bypasses SREBP1c to allow the insulin induction of FAS to continue unabated in our
conditions. This mechanism could also be through LXRα, since our results show no glucosamine
effect on the insulin and LXRα induction of FAS expression.
Our study provides very important information about how insulin resistance effects the
signaling pathways that directly regulate the metabolic pathways. Current diabetic medicines
focus on many processes that do not target the enzymes that directly regulate the metabolic
processes. For example, sodium-glucose cotransporter-2 (SGLT -2) inhibitors such as
canagliflozin help release the sugars into the kidney for excretion in the urine. Alpha glucoside
inhibitors suppress the breakdown of complex of carbohydrates into sugars to prevent glucose
from quickly entering the circulation. Other medications such as amylin and meglitinides help
insulin secretion. Metformin, one of the more popular drugs, helps increase insulin sensitivity to
stimulate glucose uptake and inhibit glucose production. However, none of the current diabetic
medicines directly address the metabolic pathways that regulate glucose homeostasis. Our study
provides important information about the regulation of G6PDH and FAS, two important
enzymes in the regulation of PPP and fatty acid synthesis respectively to help maintain glucose
homeostasis. Perhaps from our study and future studies that will evolve from it, new diabetic
medicines that address the metabolic processes that maintain glucose homeostasis will replace
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the current medicines that only help insulin sensitivity, glucose uptake, and inhibition of
glucagon release. These medicines do not currently address the core problem of the disease
which is the dysregulation of the metabolic pathways by insulin resistance. The information from
our study and future studies that evolve from it could pave the way to finding new diabetic
medicines that address the expression key metabolic pathway enzymes such as G6PDH and FAS
under insulin resistant conditions to be able to maintain glucose homeostasis in a more efficient
and better way under insulin resistant conditions, a hall mark of type 2 diabetes.
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Appendix
IACUC Approval Form for Use of Primary Rat Hepatocytes
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